Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inceptor Bio LLC
Headquarters: Morrisville, NC, United States of America
Website: https://www.inceptor.bio/
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Jul 26, 2023
Finance
July 26 Quick Takes: Versant’s Nexo launches with $60M series A round
Plus: Mirxes raises $50M series D, files for IPO in Hong Kong and updates from Kriya, Kincell, Tarsus, Infinity-MEI
BioCentury | May 9, 2023
Management Tracks
Laronde’s Cagnoni to head R&D at Incyte
Plus: Glanzmann takes the helm at Grifols and updates from Frontier, Inceptor, Zevra and AceLink
BioCentury | Mar 24, 2023
Product Development
Landscape of emerging T cell therapies in cancer
Four axes of risk map how companies founded in the last five years are innovating in CAR T and TCR T cells
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Sep 10, 2022
Discovery & Translation
A suite of liquid biopsy approaches for cancer detection and more
BioCentury’s roundup of translational news
BioCentury | May 20, 2022
Product Development
Next-gen NK cell enhancements in the clinic
Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies
BioCentury | May 20, 2022
Emerging Company Profile
Inceptor: building persistence of cancer cell therapies
Inceptor aims to address cell therapy’s challenges with $37M in series A funding, a trio of platforms and a new manufacturing facility
BioCentury | Jul 8, 2021
Product Development
July 7 Quick Takes: Moderna launches flu trial of mRNA vaccine; plus Quidel recall, NIH, WHO, Boehringer-Lilly, Novartis and more
Moderna Inc. (NASDAQ:MRNA) dosed the first participants in a Phase I/II trial of quadrivalent seasonal mRNA influenza vaccine mRNA-1010 that will help determine whether the manufacturing and efficacy
Items per page:
1 - 8 of 8